Press Releases Year: - Any -2021202020192018 Items per page 102550 July 7, 2020 at 8:30 AM EDT Summary ToggleEntera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis ‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒ ‒ Company Continues to Expect Completion of Enrollment in Q3:20 and Intends to Follow All Patients for Bone Mineral Density and Biomarker (BMD) Data May 21, 2020 at 6:30 AM EDT Summary ToggleEntera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results ‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒ ‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six Months for Bone Mineral Density Data and Evaluate Additional Higher Doses of EB613 ‒ ‒ Company May 7, 2020 at 8:30 AM EDT Summary ToggleEntera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020 Interim Three Month Top-line Biomarker Data Expected for the First 50% of Patients Enrolled in Phase 2 Osteoporosis Clinical Trial BOSTON and JERUSALEM, May 07, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, March 26, 2020 at 6:30 AM EDT Summary ToggleENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019 ‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒ ‒ Financing Completed in December 2019 Funds Company into the Second Quarter of 2021 ‒ ‒ Company to Host Conference Call and March 16, 2020 at 4:15 PM EDT Summary ToggleENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020 BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report financial and business results for the quarter and year ended December 31, 2019, on March 26, 2020, before December 18, 2019 at 4:30 PM EST Summary ToggleEntera Bio Announces the Completion of $14.3 million Private Placement BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering (the “Offering”) with a December 11, 2019 at 5:00 PM EST Summary ToggleEntera Announces Closing of Private Placement BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a private placement offering (the “Offering”) with a select group of accredited investors, including November 21, 2019 at 7:00 AM EST Summary ToggleEntera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020 Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients. Conference call and live webcast today at 8:30 am Eastern Time BOSTON and JERUSALEM, Nov. November 21, 2019 at 7:00 AM EST Summary ToggleEntera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer BOSTON and JERUSALEM , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and November 7, 2019 at 4:30 PM EST Summary ToggleEntera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019 Conference Call Scheduled for 8:30am ET / 3:30pm IST BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S. Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last